Clinical Trials Browser

Phase 2 × icotinib × 90 days × Clear all

NCT05263947 2026-02-24

Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung